Dendreon
Seattle
About Dendreon
Seattle-based biotechnology company focused on targeting cancer to transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is also developing an orally-available small molecule targeting TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Ticker: nasdaq:DNDN
- Website: dendreon.com
- Phone: (877) 256-4545
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dendreon-2818015 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.